Zeffix (lamivudine) tablets 100 mg. №28

Description

Zeffix (lamivudine) tablets 100 mg. №28

Composition

active substance: lamivudine;

1 tablet contains 100 mg of lamivudine;

Excipients: microcrystalline cellulose, sodium starch glycolate (type A), magnesium stearate, shell YS-1R-17307-A (hypromellose, titanium dioxide (E 171), yellow synthetic iron oxide (E 172), red synthetic iron oxide (E 172 ), macrogol 400, polysorbate 80).

Dosage form

Film-coated tablets.

Main physical and chemical properties: film-coated tablets, yellowish-brown, capsule-shaped, biconvex, on one side of the tablet – engraving “GX CG5”.

Pharmacotherapeutic group

Antiviral drugs for systemic use. Antiviral drugs of direct action. Nucleoside and nucleotide reverse transcriptase inhibitors. Lamivudine.

ATX code J05A F05.

Pharmacological properties

The high therapeutic potential of the drug is due to the action of its main substance – lamivudine. When ingested, lamivudine tends to accumulate in human cells as an active metabolite, lamivudine triphosphate, which is able to integrate into the DNA of viruses and inhibit their development.
Zeffix is ​​only effective against hepatitis B virus.

Indications

Zeffix is ​​used to treat chronic viral hepatitis B, which is characterized by frequent relapses.

Contraindications

Zeffix should not be used in patients with lamivudine sensitivity and renal dysfunction with creatine clearance below 50 ml / min. The drug is not used in the treatment of children under 18 years.
Special care should be taken when prescribing to patients with pancreatitis or peripheral neuropathy.

Use during pregnancy and breastfeeding
Zeffix is ​​contraindicated in women in the first trimester of pregnancy.
The drug can be used under strict medical indications in the treatment of patients from the second trimester of pregnancy and during breastfeeding.

Method of application and dose

The tablets are for oral use. The drug is used regardless of food.
Patients over 18 years of age are prescribed 100 mg once a day. The duration of treatment depends on the individual patient’s response to the drug and can vary from six to twelve months.
The drug is not recommended for use in the treatment of patients with cirrhosis or decompensated liver disease. In addition, the drug is not recommended for use in the treatment of patients who have undergone liver transplantation.
At the beginning, as well as during maintenance therapy with Zeffix, the patient’s condition should be constantly monitored by a physician experienced in the treatment of chronic hepatitis B.

Overdose

Taking Zeffix in high doses may be accompanied by increased formation of side effects. Taking high doses of lamivudine does not have a toxic effect on the body.

Side effects

Increased activity of liver enzymes, general dyspeptic disorders, epigastric pain, respiratory infections, stool disorders, increased fatigue, insomnia, increased sweating, dizziness, alopecia, joint pain, anemia, pancreatitis, peripheral anorexia, peripheral neuropathy.